Trust Company of Vermont’s Myriad Genetics MYGN Stock Holding History

Trust Company of Vermont’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2	Closed	–	–	1007
2022 Q2	$0	Buy	+2	New	+$42	﹤0.01%	909

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Trust Company of Vermont's MYGN Position: Q3 2022 in Review

Trust Company of Vermont sold out of Myriad Genetics (MYGN) in Q3 2022, closing a stake of 2 shares.

Trust Company of Vermont first reported a position in MYGN in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 191 funds tracked by Wall St. Rank hold MYGN as of Q3 2022.

Trust Company of Vermont reported no remaining Myriad Genetics position as of Q3 2022 after selling out during the quarter.
Trust Company of Vermont sold 2 Myriad Genetics shares in Q3 2022.
Trust Company of Vermont first reported a position in Myriad Genetics in Q2 2022 and held it in 1 quarter.
Trust Company of Vermont's Myriad Genetics position peaked at $0 in Q2 2022.
191 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2022.

Based on Trust Company of Vermont's 13F filing for Q3 2022, filed 24 Oct 2022.